Ligand conjugated lipid‐based nanocarriers for cancer theranostics

Rahul Kumar; Daphika S. Dkhar; Rohini Kumari; Divya; Supratim Mahapatra; Ananya Srivastava; Vikash Kumar Dubey; Pranjal Chandra

doi:10.1002/bit.28205

journal article Sep 10, 2022

Ligand conjugated lipid‐based nanocarriers for cancer theranostics

Rahul Kumar

Ananya Srivastava Vikash Kumar Dubey Pranjal Chandra

Biotechnology and Bioengineering Vol. 119 No. 11 pp. 3022-3043 · Wiley

View at Publisher Save 10.1002/bit.28205

Abstract

AbstractCancer is one of the major health‐related issues affecting the population worldwide and subsequently accounts for the second‐largest death. Genetic and epigenetic modifications in oncogenes or tumor suppressor genes affect the regulatory systems that lead to the initiation and progression of cancer. Conventional methods, including chemotherapy/radiotherapy/appropriate combinational therapy and surgery, are being widely used for theranostics of cancer patients. Surgery is useful in treating localized tumors, but it is ineffective in treating metastatic tumors, which spread to other organs and result in a high recurrence rate and death. Also, the therapeutic application of free drugs is related to substantial issues such as poor absorption, solubility, bioavailability, high degradation rate, short shelf‐life, and low therapeutic index. Therefore, these issues can be sorted out using nano lipid‐based carriers (NLBCs) as promising drug delivery carriers. Still, at most, they fail to achieve site‐targeted drug delivery and detection. This can be achieved by selecting a specific ligand/antibody for its cognate receptor molecule expressed on the surface of the cancer cells. In this review, we have mainly discussed the various types of ligands used to decorate NLBCs. A list of the ligands used to design nanocarriers to target malignant cells has been extensively undertaken. The approved ligand‐decorated lipid‐based nanomedicines with their clinical status have been explained in tabulated form to provide a wider scope to the readers regarding ligand‐coupled NLBCs.

Topics

No keywords indexed for this article. Browse by subject →

References

121

[1]

10.1039/c7ra04059h

[2]

10.1016/j.bios.2018.05.049

[3]

10.1158/1078-0432.ccr-04-2517

[4]

10.1021/bc5004313

[5]

10.1021/bc100478k

[6]

10.1016/j.biomaterials.2014.04.087

[7]

10.3109/21691401.2016.1146731

[8]

10.1016/j.msec.2017.02.114

[9]

10.1002/adhm.201200338

[10]

Targeted drug delivery to tumors: Myths, reality and possibility

You Han Bae, Kinam Park

Journal of Controlled Release 10.1016/j.jconrel.2011.06.001

[11]

10.3390/nano9030474

[12]

10.1007/s00432-014-1767-3

[13]

10.1186/1743-8977-7-3

[14]

10.1016/j.addr.2003.10.030

[15]

10.1016/j.canlet.2013.02.020

[16]

10.1016/j.jconrel.2016.06.027

[17]

10.1080/14728222.2017.1310841

[18]

10.1016/j.ejpb.2016.10.024

[19]

10.1016/j.bios.2011.11.027

[20]

10.1039/c2cc38235k

[21]

10.1016/j.bios.2011.07.038

[22]

10.1016/j.ijpharm.2015.02.070

[23]

10.1039/c2jm15830b

[24]

10.1021/acsami.7b01045

[25]

10.1002/elan.201600238

[26]

10.1097/00001703-200402000-00010

[27]

The Future of Peptide‐based Drugs

David J. Craik, David P. Fairlie, Spiros Liras et al.

Chemical Biology & Drug Design 10.1111/cbdd.12055

[28]

10.1016/j.clim.2006.06.006

[29]

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Fakhar ud Din, Waqar Aman, Izhar Ullah et al.

International Journal of Nanomedicine 10.2147/ijn.s146315

[30]

10.1007/s40262-012-0027-4

[31]

10.1158/0008-5472.can-15-1518

[32]

10.1016/j.ejpb.2011.10.015

[33]

10.1016/j.nano.2015.07.009

[34]

Gridelli C. "Erlotinib in the treatment of non‐small cell lung cancer: Current status and future developments" Anticancer Research (2010)

[35]

10.1002/smll.201402865

[36]

10.18632/oncotarget.8926

[37]

10.2174/0929867325666181008142831

[38]

10.1016/j.ultrasmedbio.2021.07.022

[39]

10.1073/pnas.95.8.4607

[40]

10.2217/nnm.12.170

[41]

10.1016/j.colsurfb.2015.06.027

[42]

10.1016/j.jconrel.2017.11.006

[43]

10.1186/1556-276x-7-462

[44]

10.1039/c8nr05099f

[45]

10.1016/j.jddst.2020.101707

[46]

10.1016/j.nano.2010.10.010

[47]

10.1016/j.jconrel.2011.09.070

[48]

10.1021/la0502084

[49]

10.1016/j.matchemphys.2022.125956

[50]

10.1016/j.mtcomm.2022.103548

Showing 50 of 121 references

Metrics

32

Citations

121

References

Details

Published: Sep 10, 2022
Vol/Issue: 119(11)
Pages: 3022-3043
License: View

Authors

R

Rahul Kumar